Related Experiment Video
Updated: Aug 6, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
Polycythemia vera: a retrospective and reprise
1Sylvester Cancer Center and the Department of Medicine, University of Miami, Florida, USA.
This article traces the history of polycythemia vera (PV) treatment, from early descriptions to the Polycythemia Vera Study Group (PVSG) trials and modern approaches. It highlights the evolution of PV management and research, including the impact of 32P and hydroxyurea.
Area of Science:
- Hematology
- Medical History
Background:
- Polycythemia vera (PV) has evolved from a poorly understood condition to a disease with established diagnostic criteria and treatment protocols.
- Early research focused on identifying PV as a distinct clinical entity and exploring initial therapeutic interventions.
Observation:
- The development of treatments for PV, including the use of 32P, chlorambucil, and phlebotomy, has been a key area of study.
- The Polycythemia Vera Study Group (PVSG) played a crucial role in conducting randomized trials to evaluate treatment efficacy.
- Concerns regarding the long-term safety of 32P (leukemogenesis) and the efficacy of hydroxyurea have prompted further research and reevaluation of treatment strategies.
Findings:
- The PVSG's first protocol established a benchmark for comparing treatments like 32P, chlorambucil, and phlebotomy.
- Research has explored alternatives to 32P, such as hydroxyurea, but its use is now being questioned.
- International study groups in France and Italy continue to advance PV research, with the Italian group developing a low-dose aspirin protocol.
Implications:
- Understanding the historical progression of PV research is essential for current and future treatment development.
- Ongoing research aims to identify safer and more effective therapies for polycythemia vera.
- The legacy of the PVSG continues to influence international collaborative efforts in PV management.
More Related Videos
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Related Concept Videos
Treatment Resistent Cancers
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Hemodialysis II: Procedure and Complications
Graves Disease II: Pathophysiology